Early blockade of joint inflammation with a fatty acid amide hydrolase inhibitor decreases end-stage osteoarthritis pain and peripheral neuropathy in mice

• Published in: Arthritis research & therapy Vol. 19; no. 1; p. 106
• Main Authors: McDougall, Jason J, Muley, Milind M, Philpott, Holly T, Reid, Allison, Krustev, Eugene
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 25.05.2017; BioMed Central; BMC
• Subjects: Amidohydrolases - antagonists & inhibitors; Animals; Arthralgia - etiology; Arthritis; Benzamides - pharmacology; Carbamates - pharmacology; Care and treatment; Complications and side effects; Diagnosis; Disease; Edema; Endocannabinoids; Fatty acid amide hydrolase; Fatty acids; Inflammation; Inflammation - etiology; Knee Joint - drug effects; Laboratory animals; Male; Methods; Mice; Mice, Inbred C57BL; Neuropathy; Osteoarthritis; Osteoarthritis - complications; Osteoarthritis - enzymology; Pain; Pain management; Patients; Peripheral Nervous System Diseases - etiology; Peripheral neuropathy; Physiology; Polyneuropathies; Risk factors; Rodents; Canada; Fatty acid amide hydrolase; Inflammation; Pain; Neuropathy; Osteoarthritis; Endocannabinoids
• ISSN: 1478-6362; 1478-6354; 1478-6362
• DOI: 10.1186/s13075-017-1313-1

The endocannabinoid system has been shown to reduce inflammatory flares and pain in rodent models of arthritis. A limitation of endocannabinoids is that they are rapidly denatured by hydrolysing enzymes such as fatty acid amide hydrolase (FAAH) which renders them physiologically inert. Osteoarthritis (OA) is primarily a degenerative joint disease; however, it can incorporate mild inflammation and peripheral neuropathy. The aim of this study was to determine whether early blockade of FAAH bioactivity could reduce OA-associated inflammation and joint neuropathy. The ability of this treatment to prevent end-stage OA pain development was also tested. Physiological saline or sodium monoiodoacetate (MIA; 0.3 mg) was injected into the right knee of male C57Bl/6 mice (20-42 g) and joint inflammation (oedema, blood flow and leukocyte trafficking) was measured over 14 days. Joint inflammation was also measured in a separate cohort of animals treated on day 1 with either saline or the FAAH inhibitor URB597 (0.03-0.3 mg/kg topical onto the knee joint). In other experiments, von Frey hair tactile sensitivity was determined on days 1 and 14 in MIA-injected mice treated prophylactically with URB597 (0.3 mg/kg s.c. over the knee joint on days 0-3). Saphenous nerve myelination was also assessed in these animals on day 14 by G-ratio analysis. Intra-articular injection of MIA caused an increase in joint oedema (P < 0.0001), blood flow (P < 0.05), leukocyte rolling (P < 0.05) and adherence (P < 0.001) on day 1 after treatment which subsequently resolved over later time points. This acute inflammatory response was ameliorated by local URB597 treatment. Prophylactic local administration of URB597 prevented MIA-induced saphenous nerve demyelination, and chronic joint pain was also attenuated. These data indicate that local inhibition of FAAH in MIA-injected knees can reduce acute inflammatory changes associated with the model. Prophylactic treatment of OA mice with the endocannabinoid hydrolysis inhibitor URB597 was also shown to be neuroprotective and prevented the development of joint pain at later time points.